RESEARCH ARTICLE

Senna makki and other active phytochemicals: Myths and realities behind covid19 therapeutic interventions

Naila Zaman, Nousheen Parvaiz, Rabia Farid, Afifa Navid, Ghulam Abbas, Syed Sikander Azam*

Computational Biology Lab, National Center for Bioinformatics, Quaid-i-Azam University, Islamabad, Pakistan

* syedazam2008@gmail.com, ssazam@qau.edu.pk

Abstract

This study aims to investigate the binding potential of chemical compounds of Senna in comparison with the experimentally tested active phytochemicals against SARS-CoV-2 protein targets to assist in prevention of infection by exploring multiple treatment options. The entire set of phytochemicals from both the groups were subjected to advanced computational analysis that explored functional molecular descriptors from a set of known medicinal-based active therapeutics followed by MD simulations on multiple SARS-CoV-2 target proteins. Our findings manifest the importance of hydrophobic substituents in chemical structures of potential inhibitors through cross-validation with the FDA-approved anti-3CL\textsuperscript{pro} drugs. Noteworthy improvement in end-point binding free energies and pharmacokinetic profiles of the proposed compounds was perceived in comparison to the control drug, vizipro. Moreover, the identification of common drug targets namely; AKT1, PTGS1, TNF, and DPP4 between proposed active phytochemicals and Covid19 using network pharmacological analysis further substantiate the importance of medicinal scaffolds. The structural dynamics and binding affinities of phytochemical compounds xanthoangelol\textsubscript{E}, hesperetin, and beta-sitosterol reported as highly potential against 3CL\textsuperscript{pro} in cell-based and cell-free assays are consistent with the computational analysis. Whereas, the secondary metabolites such as sennosides A, B, C, D present in higher amount in Senna exhibited weak binding affinity and instability against the spike protein, helicase nsp13, RdRp nsp12, and 3CL\textsuperscript{pro}. In conclusion, the results contravene fallacious efficacy claims of Senna tea interventions circulating on electronic/social media as Covid19 cure; thus emphasizing the importance of well-examined standardized data of the natural products in hand; thereby preventing unnecessary deaths under pandemic hit situations worldwide.

Introduction

Due to continuously evolving genetic makeup of the SARS-CoV-2 virus and its ability to spread rapidly, it has taken a huge toll on individuals, communities and societies across the world by ruthlessly affecting over 340 million people globally leading to 5.5 million deaths as of 20\textsuperscript{th}, January 2022 [1]. However, several vaccines worldwide namely; Oxford–AstraZeneca,
is proprietary. The Discovery studio visualizer is freely available after registration which provides limited functionality and can be used for visualizing the results of the methods performed in this study. Molecular Dynamics simulations and binding free energy calculations were performed using AMBER 16 suite. The AmberTools suite is free of charge, and its components are mostly released under the GNU General Public License (GPL). The in-house built Axial frequency distribution application is freely available that can be downloaded from http://ncb.qau.edu.pk/drsikander/AFD-1.0.0.tar.gz along with the distribution code, Readme and test files.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Pfizer-BioNTech, Sinopharm-BBIBP, Moderna, Sinovac, Johnson & Johnson, and mRNA-1273 (developed by Moderna Inc.), have been given authorization on emergency basis due to overwhelmed health systems that have caused widespread social and economic disruption [2]. Despite the rollout of vaccines to general public, trend in daily number of cases reported is still on the higher side signifying the end of the SARS-CoV-2 pandemic as implausible [3, 4]. One of the foremost reasons is the unavailability of vaccines especially in low-income and middle-income countries leading to a standstill to achieve global control of SARS-CoV-2 [5]. Another big reason is that a large number of people are reluctant to get a vaccine shot rather they believe in using herbal medicines as an alternative cure to SARS-CoV-2 [6]. Nevertheless, traditional medicinal plants have a vast history in treating infectious diseases. For example, malaria was treated for a very long time with Artemisia Annua (sweet wormwood) in China and Cinchona Officinalis (Cinchona tree) in South America [7]. Another example is the use of Chinese traditional medicine Lianhuaqingwen in the treatment of SARS-CoV-2 exhibiting inhibition of virus replication in a dose-dependent manner with IC_{50} of 411.2 μg/ml [8]. Thus, the role of herbal medicines in these unprecedented times of ongoing pandemic has resulted in a global catastrophe that cannot be ignored.

While the effectiveness of some medicinal plants has been scientifically proven, there is a global tendency for self-medication with different herbal medicines without proper scientific evidence. There has been a myth regarding the use of famous Senna tea in treatment of Covid19 that has eventually lead to its excessive use followed by a drastic hike in prices [9, 10]. It is generally used as an herbal tea made from Senna pods or leaves cultivated in different countries having different species commonly known as Alexandria Senna, Timevelly Senna, Indian Senna, and Senna Makki. The plant extracts of different species consist of many active anthraquinones and flavonoids including sennosides, aloe-emodin, rhein, iso-rhamnetin and kaempferol [11, 12]. Limitation of long term use of Senna is reported to be concomitant with dehydration and diarrhea [13]. Apprehensions on the propagation of misleading information about its use in Covid19 treatment were enhanced through social and mainstream media without sufficient scientific evidence [14]. It is of utmost importance to remove ambiguity about using Senna tea in Covid19 treatment, which can rather aggravate the symptoms by causing irritated bowel linings, dehydration, and electrolyte imbalance that can ultimately be fatal [15–17].

The scope of this study, therefore, serves to analyze potential binding of particularly those phytochemicals that have been suggested to inhibit the major protease of SARS-CoV-2, 3-Chymotrypsin-Like Protease (3CL\textsuperscript{pro}) in vitro with IC\textsubscript{50} 0–10 μM in comparison with the phytochemicals present in Senna. Inhibition of 3CL\textsuperscript{pro} is crucial in viral lifecycle and design of SARS-CoV and SARS-CoV-2 inhibitors [18]. It is highly conserved among the SARS-CoV viruses and displays 96% similarity with the zoonotic genome, especially the bat coronavirus [19, 20]. To further explore the possibility of chemical compounds of Senna to be active against other Covid19 protein targets, we elucidated its structural properties with additional essential proteins of SARS-CoV-2 namely; spike protein, helicase nsp13, and RdRp nsp12. The findings of this study will assist in distinguishing potential phytochemicals from a group of known and social media acclaimed plant based Covid19 treatments based on comparative structural dynamics. Moreover, compounds proposed in this study will hold a rationale to inhibit both PL\textsuperscript{pro} and 3CL\textsuperscript{pro} and provide avenues to use the scaffolds of these molecules in the design of more specific SARS-CoV-2 inhibitors in future.

Methodology
The complete workflow of the current study is mentioned in Fig 1.
Dataset collection for pharmacophore modeling

Training set. Two training sets were required for the generation of two pharmacophores namely, 3D-QSAR pharmacophore and common feature pharmacophore. A dataset consisting of diverse structural information with in vitro data on medicinal plants that have exhibited high potential in inhibiting 3CL\textsuperscript{pro} was collected from different resources and used for the generation of 3D-QSAR pharmacophore [21–23]. The inhibitory studies conducted on SARS-CoV-2 reported the IC\textsubscript{50} value of chloroquine between 1.13 to 5.47 μM [24], thus establishing a threshold to include those medicinal compounds that exhibited IC\textsubscript{50} value from 0–15 μM. Training set for the generation of 3D-QSAR pharmacophore is mentioned in the S1 Table. Whereas, Senna compounds constituting phenolic acids, flavonoids, and coumarins with the highest quantity of benzoic acid as well as anthraquinones were used in the training set to generate a common feature pharmacophore (S2 Table).

Test set. To validate the generated pharmacophores, we investigated both the known active and inactive medicinal compounds between IC\textsubscript{50} values 1.2 μM to 226 μM. Moreover, to randomize the test set, a set of 77 known active and inactive FDA-approved compounds recently released against 3CL\textsuperscript{pro} by the National Center for Advancing Translational Sciences (NCATS) ("SARS-CoV-2 cytopathic effect (CPE)", 2021) [25] were also added in the test set. To keep the study consistent with experimental results, we particularly added the controls reported in multiple in vitro studies including hesperetin (8.3 μM), aloe-emodin (132 μM), apigenin (280.8 ± 21.4 μM), luteolin (20.0 ± 2.2 μM), quercetin (23.8 ± 1.9 μM), and remdesivir (5 μM) [26].
Pharmacophore modeling

All the protocols such as; 3D-QSAR pharmacophore modeling, common feature pharmacophore modeling, ligand pharmacophore mapping, and feature mapping were carried out with the BIOVIA Discovery Studio (DS) [27]. In this study, we generated two pharmacophore models; 1) 3D-QSAR pharmacophore model for biologically active phytochemicals reported against 3CL\textsuperscript{Pro} and 2) a common feature pharmacophore for \textit{Senna} compounds with no reported experimental activity with a given target. 3D-QSAR pharmacophore generation protocol that is designed to generate predictive pharmacophores based on ligands with known activity against a specific biological target was run with input ligands set to a training set of 27 active phytochemicals against 3CL\textsuperscript{Pro}. The HypoGen algorithm generated 200 conformations with an energy threshold for each ligand maintained within a 10 kcal/mol energy range that were further optimized using simulated annealing. The ligands in the dataset used pre-defined ‘Activ’ and ‘Uncert’ values. ‘Activ’ refers to the tested biological values of the input ligands (IC\textsubscript{50}). Whereas; ‘Uncert’ that is the uncertainty value was set to 1.5 implying the variation between experimental and estimated values during model generation up to two times and also affects the regression fitting of the pharmacophores during optimization. Moreover, to determine the best features that should be considered during the pharmacophore models generation, we used a Feature mapping tool that maps solvent-accessible features and identifies all possible locations of the selected pharmacophore features on the given ligand. The parameters for “Max” and “Min” in the feature mapping protocol were set to 5 and 1, respectively. The results exhibited hydrogen bond acceptor (HBA), hydrogen bond donor (HBD), hydrophobic (HYD), positive ionizable (PI), and ring aromatic (RA) features as commonly mapped features from the training set compounds.

However, in the absence of biologically predicted values for \textit{Senna} compounds against 3CL\textsuperscript{Pro}, a common feature pharmacophore was generated with the phytochemicals of \textit{Senna} presented in S2 Table. We assumed all compounds to be equally active that were considered as reference ligands exhibiting HBA, HBD, HYD, PI, and RA as common features as a result of the feature mapping tool analysis. The protocol carried out both the model generation with a training set and validation with a test set simultaneously. The output file lists the SD file for each pharmacophore aligned to the ligands and the receiver operating characteristic (ROC) curve exhibiting the trade-off between sensitivity and specificity of selected pharmacophores. Each pharmacophore uses the FitValue property to ascertain which ligand uses the maximum features for mapping. Higher FitValue is indicative of more features mapped in a suitable conformation.

Pharmacophore validation

Two methods: the cost analysis and test set analysis were used to determine the best 3D-QSAR pharmacophore models. A test set of ligands with similar receptor binding that was not used for model generation was employed to assess the ability of generated pharmacophores to estimate activity of test ligands. The protocol to generate a 3D-QSAR pharmacophore model for the given training set and validation with a test set takes place simultaneously in BIOVIA DS resulting in a detailed report with 10 hypothesis models generated with different statistical parameters. The output file contains an SD file of the input ligands aligned to each pharmacophore with a report summary that includes regression statistics and a plot of LogEstimate vs. LogActiv for the test ligands to quickly determine the best pharmacophore with the ability to predict the activity of test ligands. Whereas; for the cost analysis, the overall cost of each hypothesis was calculated by summing these 3 cost factors; 1) FitValue property that indicates the total number of features mapped that are HBA, HBD, HYD, PI, and RA 2) high correlation
coefficient (r^2), 3) lowest total cost while exhibiting highest cost difference and 4) low root mean square deviation (RMSD) values. Another method ligand pharmacophore mapping protocol was run with the test ligands as input to validate the performance of selected pharmacophores and return an estimated value that should be close to the experimental values. It anticipates the activity of selected pharmacophore based on a decent correlation coefficient with the test set ligands and 95% cross-validation confidence.

However, to determine the best common pharmacophore model and to quickly identify the matches, a ligand profiler protocol was used with input data set to test set that was mapped against the generated common feature pharmacophores. Ligand profiler generates a heat map to quickly determine the best set of ligands mapped against a pharmacophore based on the Fit-Values. From the heat map, the pharmacophores that do not map to any of the test set compounds can be easily identified, making the selection of pharmacophores easier with higher FitValue and more relevant alignment. The validated pharmacophores were subsequently used for lead identification from the molecular libraries.

**Virtual screening for lead identification**

The selected 3D-QSAR pharmacophore model was used to screen a library of 2,287 compounds comprising alkylated chalcones, phlorotannins, tanshinones, bioflavonoids, and flavonoids. Whereas, the common feature pharmacophore model was used to screen a library of in-house built **Senna** compounds collected using the Chembl similarity searching tool [28] against sennosides and anthraquinones present in **Senna**. We chose 3D-QSAR pharmacophore model Hypo1 and the common feature pharmacophore model 10 as a 3D query to screen the input ligands against each pharmacophore feature present in the query to extract the more relevant pharmacophore models. The screen library protocol in BIOVIA DS was used with the minimum features parameter set to 3, the maximum features parameter set to 4, and the maximum subset of pharmacophore parameter set to 100. This suggests that 100 pharmacophore subsets of all possible 3 and 4 feature pharmacophore from the 5 features will be used for screening. The resulting subset of both the libraries was then subjected to molecular docking.

**Molecular docking**

LiDock algorithm of BIOVIA DS was run to dock the screened ligands from 3D-QSAR pharmacophore of phytochemicals and common feature pharmacophore consisting of **Senna** compounds separately. The screened compounds against 3D-QSAR pharmacophore were reported specifically as anti-3CL^\text{pro}\text{ ligands with known biological activity, thus they were not tested for other Covid19 targets and subjected to docking into the active site His164 of 3CL^\text{pro} [29]. LiDock calculates a hotspot map for the given receptor site containing polar and apolar groups, which are used to generate favorable ligand-receptor interactions followed by the energy minimization step. Due to the conformational differences in the monomeric and dimeric structure of 3CL^\text{pro}\text{ as suggested in the literature [30], we subjected all the complexes to MD simulations with the monomer; whereas, only those compounds were tested with dimer that were unstable with monomer. Moreover, due to the absence of any experimental data on screened compounds sennoside A, B, C, and D of **Senna** against 3CL^\text{pro}, we expanded our research scope and chose four additional proteins that are crucial for the survival of SARS-CoV-2 namely; spike protein (PDB: 6LZG), helicase nsp13 (PDB: 6JYT), RdRp nsp12 (PDB: 6M71) and 3CL^\text{pro} (PDB: 6LU7). In order to validate further, based on dynamics and conformational changes, we selected three FDA-approved drugs against Covid19 namely; remdesivir, hydroxychloroquine, and vizimpro [31], which were used as a control. The top-scoring compounds
from each dataset were then subjected to molecular dynamics (MD) simulations with Amber16 [32].

**Molecular dynamics simulations**

MD simulations were carried out on the active phytochemicals, vizimpro and *Senna* compounds to check the behavior of protein with their proposed ligands. There were 6 phytochemicals and vizimpro in complex with 3CL\textsubscript{pro}, 2 complexes of spike protein (docked at both the regular and allosteric site), helicase nsp13, RdRp nsp12, and 3CL\textsubscript{pro} with *Senna* compounds. For this purpose, parameter/topology files were generated using the LEaP program followed by the system preparation by neutralizing it with counter ions (Na\textsuperscript{+} /Cl\textsuperscript{-}). TIP3P tetrahedral solvation box was adjusted for 12 Å and General Amber Force Field (GAFF) and ff14SB was used to get insights into the intermolecular and intramolecular interactions. Furthermore, in the next step, pre-processing was performed for all the systems with 500 steps and 1000 cycles of minimization with 200kcal/mol/Å\textsuperscript{2}. The whole system’s atoms were again minimized for 1000 cycles with 5kcal/mol/Å\textsuperscript{2} by applying restraints on carbon alpha atoms, while 300 minimization steps were run for non-heavy atoms to further relax the system. The system was slowly heated with restraints on the backbone and restraint weight 5 kcal/mol/Å\textsuperscript{2} using Langevin dynamics till 300 K. The system was then equilibrated for 100 ps to make it stabilized according to the environment. The pressure was sustained through the NPT ensemble allowing the restraint weight of 5kcal/mol/Å\textsuperscript{2}. All these systems then underwent production run of minimum 200 ns with a non-bounded cut-off set to 8.0 Å. However, only those systems were extended that exhibited instability in their RMSD trend mentioned in S7 Fig.

**Trajectories analysis**

The generated trajectories were analyzed through Amber CPTRAJ module 16 to observe the stability of the complex. Different parameters such as RMSD, root mean square fluctuations (RMSF), beta-factor (β-factor), and radius of gyration (Rg) were calculated. The generated graphs and trajectories were analyzed using the Visual Molecular Dynamics [33] and Chimera [34].

**Binding free energies**

Binding free energies were calculated using the MMPBSA/GBSA package of Amber16 [35], which used the generated trajectories of MD simulations and subjected them to MM(PB/GB) SA.py module [36]. The system works by calculating the energy difference between complex, unaided protein and ligand. The MMPBSA.py module was used to generate the prmtop files of protein, ligand, and complex, which subsequently follow the total binding energies calculation and decomposition binding free energy calculations. The total 450 frames each after every 0.2 seconds were mined from the entire MD trajectories and exposed to MMPBSA calculations. Poisson-Boltzmann (PB) or Generalized-Born (GB) approaches were used to accomplish the analysis. The binding free energy provides information about the significant residues that help to analyze the components that participated in keeping the protein and ligand intact. Furthermore, these binding energies were decomposed into per residue using the MMPBSA.py module of Amber 16.

**Axial frequency distribution**

The axial frequency distribution (AFD) was employed to have insights about the positioning of ligand with respect to coordinates. It gives a detailed assessment of binding pattern of ligand
by providing insights into distribution of atoms of ligands with respect to the x and y coordinates. To run AFD, the protein atom was chosen as a point of reference, and a 3D histogram was generated. The axial distribution of atoms is represented through the following equation:

$$AFD = \sum_{i=1, j=1}^{k, l} m_{i,j}$$

Where, i and j represent the coordinates of ligand atoms on X and Y plane, respectively, k and l represent the cutoff values on X and Y plane, whereas $m_{i,j}$ is the number of observations for i and j coordinates [37].

**Toxicity analysis**

ADMET protocol of BIOVIA DS software was used to calculate the ADMET properties of selected compounds whereas; TOPKAT suite of BIOVIA DS software carried out the toxicity prediction based on built-in and validated rodent models. The parameters such as solubility level, absorption level, blood-brain barrier (BBB) penetration level, plasma protein binding (PPB) prediction with a cutoff score of -2.209, CYP2D6 (cutoff score 0.161), and hepatotoxic prediction using a cutoff value of -4.154 were calculated. Moreover, the TOPKAT calculated toxicity based on validated models present in BIOVIA DS such as; FDA rodent carcinogenicity test, the prediction of tumorigenic dose rate 50 (TD50) of a drug, rat maximum tolerated dose (MTD), test rat oral acute median lethal dose (LD50) of a chemical, prediction of rat chronic lowest observed adverse effect level (LOAEL), ocular and skin irritancy.

**Network pharmacological analysis**

The network pharmacological approach was used to decipher the signaling pathways associated with target proteins of proposed phytochemicals against Covid19. Proposed phytochemicals including *Senna* compounds were subjected to http://www.swisstargetprediction.ch/ to identify the drug targets. Whereas, the DisGeNET (http://www.disgenet.org/) disease target prediction analysis platform was used to find the drug targets of Covid19. Drug targets that were common between Covid19 and phytochemicals were selected and merged by Cytoscape3.9.1 software to construct an active ingredient-key targets Covid19 network.

**Results**

**Pharmacophore modeling**

Ligand-based 3D-QSAR pharmacophore modeling resulted in the generation of 10 hypotheses that aligned to the ligands present in training set. The best hypothesis Hypo1 was selected based on the highest correlation value of 0.74, highest cost difference of 115.21, and the lowest RMSD of 1.39 Å. The statistical values of 10 hypotheses are summarized in Table 1. The highest cost difference values indicate the ability of pharmacophore to predict estimated values with respect to experimental values with 90% significance. The selection of best pharmacophore model was also based on the highest FitValue of 4.36 that is based on the alignment of training set ligands to the pharmacophore. Four common features consisting of 1 HBA, 2 HYD, and 1 RA were observed in Hypo1 as presented in S1 Fig. It was noted that all the features of pharmacophore were mapped to the most active medicinal compound xanthoangelol_E having $IC_{50} = 1.2 \pm 0.4 \mu M$, depicted in S1 Fig. Moreover, a list of Hypo1 estimated and experimental values with their corresponding error values against medicinal compounds are also given in Table 2. Interestingly, it was also noted that among the four features, only RA was
missing from other active phytochemicals endorsing the importance of HBA and HYD features, which might be responsible for the experimental activity.

However, in the case of Senna compounds, it was observed that the common feature pharmacophore no. 10 aligned with the training set compounds with highest FitValues exhibiting 3 HBA and 1 RA features as presented in S2 Fig. The compound isoquercetin mapped to the common feature pharmacophore with highest FitValue of 0.975 as displayed in S2 Fig. However, it is noteworthy that the presence of hydrophobic pockets and basic residues in 3CLPro have been reported in the literature [29], highlighting the significance of hydrophobic features, which is missing in the case of common feature pharmacophore.

### Table 1. Statistical parameters of top 10 3D-QSAR pharmacophore hypotheses generated using HypoGen algorithm.

| Hypothesis No. | Total Cost | Cost Difference | RMSD<sup>b</sup> | Correlation | Features<sup>c</sup> |
|---------------|------------|-----------------|------------------|-------------|---------------------|
| 1             | 125.43     | 115.2           | 1.39             | 0.741       | HBA, HP, RA         |
| 2             | 129.24     | 111.39          | 1.44             | 0.729       | HBA, HP, RA         |
| 3             | 137.88     | 102.76          | 1.52             | 0.707       | HBA, HP, RA         |
| 4             | 141.68     | 98.961          | 1.55             | 0.697       | HBA, HP, RA         |
| 5             | 145.10     | 95.537          | 1.57             | 0.691       | HBA, HP, RA         |
| 6             | 145.21     | 95.429          | 1.58             | 0.689       | HBA, HP, RA         |
| 7             | 146.72     | 93.917          | 1.60             | 0.682       | HBD, HP             |
| 8             | 153.04     | 87.594          | 1.65             | 0.667       | HBA, HP, RA         |
| 9             | 154.81     | 85.827          | 1.68             | 0.660       | HBA, HP, RA         |
| 10            | 157.02     | 83.620          | 1.75             | 0.653       | HBD, HP             |

The null cost and the fixed cost are 240.64 and 109.19, respectively

<sup>a</sup> Cost difference between the null and the total cost

<sup>b</sup> RMSD, root mean square deviation

<sup>c</sup> Abbreviation used for features: HBA, hydrogen bond acceptor; HYD, hydrophobic; RA, Ring Aromatic.

https://doi.org/10.1371/journal.pone.0268454.t001

### Table 2. Predicted and experimental IC<sub>50</sub> values of the training set compounds based on the 3D-QSAR Hypothesis 1 pharmacophore model.

| Name              | FitValue | Predicted IC<sub>50</sub> (μM) | Experimental IC<sub>50</sub> (μM) | Error | Status        | Mapping |
|-------------------|----------|--------------------------------|----------------------------------|-------|---------------|---------|
| Xanthoangelol_E   | 4.36     | 1.60                           | 1.20                             | 1.40  | active        | [6 20 12 9] |
| Hesperetin        | 3.68     | 6.60                           | 8.30                             | 1.50  | active        | [1 23 14 *] |
| Iguesterin        | 3.08     | 8.10                           | 2.70                             | 3.10  | active        | [2 25 4 *]  |
| Dieckol           | 3.14     | 5.70                           | 2.70                             | 2.10  | Moderately active | [12 37 33 *] |
| Tanic acid        | 2.12     | 61                             | 3.00                             | 20    | moderately active | [11 * * 61] |
| Psoralidin        | 3.71     | 5.30                           | 4.20                             | 1.30  | moderately active | [5 23 17 *] |
| Tomentin          | 3.00     | 7.90                           | 5.00                             | 1.60  | moderately active | [3 32 21 *] |
| Pristimerin       | 3.07     | 6.70                           | 5.50                             | 1.20  | moderately active | [2 33 24 *] |
| Amentoflavone     | 3.00     | 8.00                           | 8.30                             | -1.0  | moderately active | [9 21 * 13] |
| Tingenone         | 2.81     | 12                             | 9.9                              | 1.20  | moderately active | [3 25 5 *]  |
| Betulinic acid    | 3.03     | 7.30                           | 10                               | -1.40 | moderately active | [1 31 14 *] |
| Diplacone         | 3.11     | 6.1                            | 10                               | -1.70 | moderately active | [6 29 16 *] |
| Celastrol         | 2.74     | 15                             | 10                               | 1.40  | moderately active | [4 16 18 *] |
| Dihydro tanshinone | 2.18     | 53                             | 14                               | 3.70  | moderately active | [* 15 * 1]  |
| Mimulone          | 3.13     | 5.80                           | 14                               | -2.50 | moderately active | [5 22 15 *] |

*Refers to the missing features.

https://doi.org/10.1371/journal.pone.0268454.t002
Validation of pharmacophore models

Validation of any 3D-QSAR hypothesis model is primarily based on the cost analysis of two theoretical values 1) total cost value and 2) null cost value. A good quality pharmacophore has a cost difference of 40 to 60-bit score representing 70–90% confidence level along with other important parameters such as lowest RMSD and the highest correlation values. However, the 3D-QSAR model selected in this study represents the probability of more than 90% correlation among the data sets with the highest total cost difference 115.21 and highest correlation value 0.74, exhibiting a pharmacophore model with high prediction ability for lead identification.

Apart from the cost analysis of the training set, the 3D-QSAR pharmacophore model was validated using error values estimated between the experimental and estimated activity values generated as a result of the ligand pharmacophore mapping protocol. 33 test set compounds mapped to Hypo1 pharmacophore with error value of $<10$ depicting order one difference between the experimental and estimated IC$_{50}$ values. The statistical analysis indicated higher regression coefficient ($R^2$) value of 0.646 for the test set while cross-validating the results with training set that displayed regression coefficient value $R^2 = 0.495$, depicted in Fig 2.

![Training Set](https://doi.org/10.1371/journal.pone.0268454.g002)

![Test Set](https://doi.org/10.1371/journal.pone.0268454.g002)

Fig 2. Correlation graph in logarithmic scale for experimental values vs. predicted values of training and test ligands that mapped the 3D-QSAR pharmacophore model Hypo1.
Moreover, the FDA-approved drugs, vilazodone and lapatinib both having IC\textsubscript{50} of 10 μM from the test set mapped the 3D-QSAR pharmacophore model highest FitValue of 3.56 as depicted in S1 Fig. From these results, it was conceived that the presence of chemical features HBA, HYD, and RA for 3CL\textsuperscript{pro} inhibitory activity are crucial and are also found in FDA-approved drugs currently under clinical trials. Furthermore, in the case of common feature pharmacophore modeled for the \textit{Senna} compounds, the ROC curve was used to evaluate the degree of false positivity of the model with known active and inactive compounds. The curve plots true positives against false positives and indicates if the model predicted active compounds higher than the inactive compounds. The AUC value lies between 0 and 1; 0 is indicative of a bad classifier, however, the selected model exhibited a fair accuracy score of 0.710 as presented in Fig 3. S3 Table displays sensitivity and specificity values of the selected model with an ability to distinguish between active and inactive compounds. Additionally, the results of ligand profiler protocol exhibited mapping of 15 test set compounds accurately with the selected pharmacophore and labeled active compounds as red and inactive as blue that can be seen in Fig 3. It is therefore determined from the validation results that both pharmacophore models exhibited the capability to classify active and inactive compounds. The 3D-QSAR pharmacophore model however exhibited all the significant features that are required for binding of 3CL\textsuperscript{pro}, while the common feature pharmacophore model failed to identify hydrophobicity as a common feature.

**Virtual screening**

The validated 3D-QSAR Hypo1 model and the common feature pharmacophore model No. 10 were used as a query to screen for new lead compounds from the medicinal library of 2,287 compounds and \textit{Senna} compounds. The compounds from the virtual screening that best
mapped to the pharmacophore models were selected based on the highest FitValues. The compounds with FitValue ranging from 3.98–2.46 from each library were selected and subjected to molecular docking.

**Molecular docking**

Since 3D-QSAR pharmacophore was generated with respect to only one target, the resulting compounds from virtual screening along with the 27 training set compounds of the active phytochemicals were subjected to molecular docking with 3CL\textsuperscript{pro}. The top six compounds; xanthoangelol\textsubscript{E} with the highest LibDock score of 202, beta-sitosterol with a score of 198, hesperetin with a score of 152, luteolin-7-O-glucopyranoside, isoquercetin, and calceolarioside\textsubscript{B} with LibDock score 124, 114, and 112 from the medicinal library were chosen, respectively. However, considering the fact that theoretically one of the tea ingredients of *Senna* may bind a different Covid19 protein and/or key cellular protein, it was necessary to expand our research to determine the binding potential of *Senna* compounds. Therefore, the *Senna* compounds screened for common feature pharmacophore that does not require a specific target for model building were subjected to docking with four additional proteins (both structural and non-structural) of Covid19. The standing of selected proteins in the structure of Covid19 virion is presented in Fig 4. The docked compounds present in high quantity in *Senna* namely; sennoside A, B, C, and D were chosen for further analysis on the basis of LibDock score against each target protein. Herein; we also subjected three recently approved FDA drugs remdesivir, hydroxychloroquine, and vizimpro to molecular docking to validate results based on comparative analysis. However, the topmost compound vizimpro with the highest docking score of 129 was further subjected to MD simulations to further validate representative pharmacophore models and demonstrate their efficiency.

![Fig 4. SARS-CoV-2 virion with the four selected proteins. The structure of virion is taken from [40].](https://doi.org/10.1371/journal.pone.0268454.g004)
Active phytochemicals

The topmost compound, xanthoangelol_E is an alkylated chalcone capable of inhibiting both 3CL$^{pro}$ and PL$^{pro}$ in a significant dose-dependent manner with IC$_{50}$ ranging from 1.2 ± 0.4 to 46.4 ± 7.8 μM [38]. Xanthoangelol_E completely occupied the catalytic pocket of 3CL$^{pro}$ making interactions with all the sub-pockets S1, S2, S3, S4, and S5 as depicted in S3 Fig. Whereas, the second and third topmost compounds; beta-sitosterol, and hesperetin, are phytochemicals with reported inhibitory activity for 3CL$^{pro}$ with IC$_{50}$ 115 μM and 8.3 μM, respectively [39]. Both these compounds exhibited strong hydrogen bond interactions with significant residues of 3CL$^{pro}$ such as Glu166, Thr190 and His164 presented in S3 Fig while occupying the sub-pockets S3, S4 and S5. Beta-sitosterol also exhibited other significant interactions such as alkyl, pi-alkyl, and pi-pi T-shaped with residues Leu50, Leu167, Ala191, Met165, Pro168, and His41, respectively. Whereas, hesperetin not only exhibited interactions with the catalytic dyad but the–OH substitutes displayed strong hydrogen bond interactions with Arg489, Gln493, His464, and Leu442.

Furthermore, the fourth topmost compound is luteolin-7-O-glucopyranoside, which is a phytochemical essentially a derivative of luteolin and cynaroside. Luteolin is commonly known for its anti-inflammatory activities both in vitro and in vivo based on its pharmacologically competent mechanism of action [41]. The glucopyranoside ring of this compound targeted the sub-pockets S1 and S3 while exhibiting interactions with His163, Glu166, and Gln192 as depicted in S4 Fig lying near the catalytic dyad (Cys145- His41). Whereas, the fifth compound, a hydroxycinnamic acid, calceolarioside_B exhibited potential binding affinity with the sub-pockets S1, S2, and S3. The oxygen atoms of the ligand molecule have shown conventional hydrogen bond interactions with Asn142, His41, and Gln143 residues of the binding pocket depicted in S4 Fig. Moreover, the last topmost docked compound, isoquercetin, which is a secondary metabolite from a class of flavonoids, exhibited hydrogen bonding between the aromatic ring of quercetin and the neighboring residues Gln189, Gln192, Val186, and Arg188 as depicted in S4 Fig. Our analysis identified 6 significant active phytochemicals that exhibited strong binding interactions with 3CL$^{pro}$ catalytic triad Cys145-His41 and Glu166. However, the role of Glu166 and the neighboring residues in anchoring the sub-pockets of active site and dimerization of 3CL$^{pro}$ has been regarded as critical by [42, 43], which is analyzed during MD simulation studies in detail.

Senna compounds

To get insights into the binding potential of Senna compounds, they were subjected to docking with four additional essential proteins of SARS-CoV-2 to conclude and convey the larger significance of this study.

3CL$^{pro}$. The docking results of 3CL$^{pro}$ with Senna compounds presented in Fig 5 exhibit conventional hydrogen bond interactions with residues Gly170, Gly138, Lys5, Val125, and Glu288 with Libdock score of 109. Compared to the docking results of active phytochemicals against 3CL$^{pro}$, Senna has shown weak binding affinity and few intermolecular interactions suggesting that this might not be a potential lead compound for the inhibition of target protein.

Helicase Nsp13. Nsp13 is an interesting drug target as it plays a crucial role in the transcription-replication complex of CoVs. Docking of Senna compounds against helicase nsp13 has resulted in the Libdock score of 114. Significant hydrogen bond interactions of oxygen atoms of the ligand can be observed in Fig 5 with residues Glu377, Ser312, Gln539, Ser541, Thr288, Arg445, and Glu321. Furthermore, Ala314 and Ala318 were involved in pi-alkyl interactions with benzene ring of the ligand playing a crucial role in adjusting and anchoring the ligand within the binding pocket.
RdRp Nsp12. Non-structural proteins such as nsp12 are highly conserved proteins, which are essential for viral infection. Senna compounds have shown a Libdock score of 102 against RdRp nsp12. Active pocket residues Trp617, Lys798, Asp760, Cys622, Lys551, and Lys621 have made crucial hydrogen bond interactions with the oxygen atoms of the ligand as depicted in Fig 5. Furthermore, the benzene ring of the ligand has made pi-anion interactions with Asp618.

Fig 5. Preferred binding modes of sennosides docked with four essential proteins of SARS-CoV-2 depicting 2D binding interactions. a) 3CLpro b) Helicase nsp13 c) Spike protein-ACE2 receptor complex docked at two different sites d) RdRp nsp12.

https://doi.org/10.1371/journal.pone.0268454.g005
Spike protein. Spike protein aids in the attachment of virus to the host cell and thus is a significant drug target for inhibition studies. Docking of Senna compounds against receptor-binding domain (RBD) of spike protein bound with ACE2 receptor resulted in Libdock score of 118. The active site residues involved in crucial interactions with the protein are Asp30, Gly416, Arg408, His34, Ser494, Tyr495, Glu37, Ala387, and Tyr421. Significant hydrogen bond interactions of binding site residues with ligand oxygen atoms have firmly anchored the ligand within the active pocket as depicted in Fig 5.

Furthermore, several other intermolecular interactions such as pi-anion and pi-alkyl between receptor and ligand have also contributed to enhanced binding affinity. Moreover, to analyse the conformational changes in spike-ACE2 complex and to estimate the capability of Senna compounds to disrupt interactions between spike protein and ACE2 receptor, molecular docking at the allosteric site of spike protein has revealed a Libdock score of 126. Protein residues Ala330, His356, Glu357, Asp332, and Asn376 have exhibited strong hydrogen bonding interactions with the lead compound. However, Glu384 has exhibited pi-anion interactions with two benzene rings of the ligand.

Molecular dynamics simulations

All the complexes including vizimpro (the control) were subjected to MD simulations to have insights into the dynamics and conformational stability of active phytochemicals in complex with the SARS-CoV-2 3CL\(_{pro}\) and Senna compounds with 3CL\(_{pro}\), RdRp nsp12, helicase nsp13, and spike-ACE2.

Analysis of active phytochemicals. The first compound beta-sitosterol exhibited noteworthy results during 200 ns of MD simulations. It possess stability with both the chains A and B throughout simulations and moved even deeper in the binding pocket of 3CL\(_{pro}\) as displayed in Fig 6. Interestingly, beta-sitosterol was observed making alkyl and pi-alkyl interactions more often with the residues of the active site with an average RMSD of 1.78 Å, Rg 22.2 Å and β-factor 31.6 Å as exhibited in S5 Fig. The influence of electrostatic interactions in attaining conformational stability has been explained in the literature several times [44], proposing beta-sitosterol as an interesting candidate for further analysis.

Whereas, the second compound hesperetin was run for 200 ns and exhibited stability for the first 60 ns followed by a sudden increase in RMSD resulting in detachment of hesperetin.
from chain A, while remaining intact with chain B of the dimer as depicted in Fig 7. Average RMSD of 1.35 Å is shown in S5 Fig, which also exhibits the maximum fluctuations observed mainly in domain III with the Rg value 22.1 Å and β-factor 25.8 Å. Nonetheless, the role of critical residues such as His143, Phe140, Gln189, and Glu166 was again highlighted as they were involved in making significant interactions with chain B of 3CL<sub>pro</sub>.

Similarly, xanthoangelol_E, the most active medicinal compound reported in experimental assays against 3CL<sub>pro</sub> exhibited the same behavior as hesperetin. However, increase in trend of RMSD graph was observed till 200 ns, which was extended to 300 ns to corroborate the structural dynamics (see S7 Fig for extended simulations). The ligand stayed intact with only chain B of the dimer protein displaying overall stability in protein structure as shown in Fig 7. However, the active site residues of chain B were actively involved in making interactions with xanthoangelol_E with an average RMSD of 2.04 Å as displayed in S5 Fig.

Furthermore, the structural and conformational dynamics of luteolin-7-O-glucopyranoside during 200 ns exhibited extraordinary results with an average RMSD of 3.03 Å exhibiting the formation of 13 hydrogen bonds between glucopyranoside ring and the active site residues of 3CL<sub>pro</sub>. A significant increase was observed between 50 ns to 75 ns with the highest peak noted at 65<sup>th</sup> ns with an RMSD value of 6.07 Å. This noticeable change can be visually observed in simulation trajectories where increased bonding with the loop region (185–200 residues) that connects domain II to domain III caused the third domain to open up as displayed in Fig 8. Moreover, the number of bonds formed by the ligand significantly increased from 9 to 22, of which, 13 were hydrogen bonds while the rest comprised of C-H bonds and pi-alkyl bonds. The protein was seen to open up to incorporate the ligand into its binding pocket completely at 10 ns forming and breaking hydrogen bonds after every 10 ns up to 75 ns. However, after 80
ns, strong hydrogen bonding was observed stabilizing the RMSD as presented in S6 Fig making domain III returned to original position with the aid of residues Thr190 and Ala191 that kept the critical residues of the active site intact.

The next simulation run with isoquercetin, exhibited fluctuations in domain II and domain III resulting in increased RMSD at 150 ns therefore MD simulations were extended to 300 ns to confirm the structural stability of this complex (see S7 Fig for extended simulations). However, after 200 ns, it was observed that isoquercetin detached from the active site resulting in instability of the complex. Furthermore, the last MD simulation run of calceolarioside_B with 3CL\textsuperscript{pro} exhibited significant fluctuations in RMSD throughout the 200 ns run. The simulations were further extended to 400 ns to explore the stability of the compound in its binding pocket (see S7 Fig for extended simulations). Results yielded showed that a significant rise of RMSD at 250 ns is associated with domain III movement covering 21.6 Å from its initial position as depicted in Fig 8. The ligand adjusted itself in the binding pocket of the receptor to form strong hydrogen bond interactions with crucial residues Glu166, which play a central role in making interactions with a catalytic dyad (Cys145 and His41) and is critical for the proteolytic activity of the viral protein [45, 46]. However, further insights into the simulation results show that the domain moved back to its original position after 300 ns leading to stabilization in RMSD. All the 6 compounds were further compared with a control vizimpro based on MD simulation results, which exhibited the exact behavior between chain B (1–302 residues) of vizimpro and the dimer 3CL\textsuperscript{pro}. The ligand from chain A drifted away from the active site after 150 ns. Whereas, the ligand tightly attached itself to chain B and completely occupied the active site while moving inside the cavity making even stronger interactions with the active site residues of the receptor. Our analysis was further extended to the calculation of binding free energies of all the 7 complexes using MMPBSA and MMGBSA calculations to conclude our study.

Analysis of Senna compounds. Five complexes were subjected to MD simulations comprising a span of 200 ns each. The first simulation run with 3CL\textsuperscript{pro} exhibited detachment of sennoside (ligand) from the active site as depicted in Fig 9. However, the second most
interesting complex with spike protein and ACE2 receptor was analysed with two different sites to identify the conformational changes if any. Ligand bound at RBD of spike protein exhibited stability till 200 ns exhibiting the inability of ligand to abrogate interactions between the spike protein and ACE2 receptor of SARS-Cov-2 as shown in Fig 9. However, the ligand docked at the allosteric site of ACE2 receptor resulted in protein fluctuations but eventually detached itself from the active site after 150 ns as shown in Fig 9. As an outcome, interactions between spike protein and ACE receptor were not abolished that are essential for its inhibitory activity [47, 48]. The same results were observed with RdRp nsp12 and helicase nsp13 complexes. None of the active sites retained sennosides probably due to the absence of hydrophobic interaction, which were reported in different studies as significant for inhibitory activity of SARS-CoV-2 proteins [49, 50]. Moreover, the Senna compounds that remained intact with the protein even farther from the active site were still subjected to binding free energy profiles to get insights into the energetics between proteins and ligands; respectively.

**Binding free energy analysis**

The end-point free energy calculations were performed to find energetics between active phytochemicals in complex with 3CL<sub>PrO</sub>, Senna compounds in complex with RdRp and spike-ACE2, and vizimpro. The distribution of energetics of top three active phytochemicals xanthoangelol, beta-sitosterol, and hesperetin as a result of MMGBSA calculations is mentioned in Table 3. The sum of binding free energy with a dimer 3D structure of 3CL<sub>PrO</sub> as a result of MD simulations of sennosides with a) 3CL<sub>PrO</sub>, b) Spike-ACE2 with ligand attached at RBD, c) Spike-ACE2 with ligand attached at allosteric site, d) RdRp nsp12, and e) Helicase nsp13.

![Figure 9](https://doi.org/10.1371/journal.pone.0268454.g009)

Table 3. Binding free energy and its components in MM/GBSA and MM/PBSA for the active phytochemicals, Senna compounds, and vizimpro in complex with 3CL<sub>PrO</sub>, RdRp, and spike-ACE2 proteins in kcal/mol.

| Energy Components | Vizimpro 3CL<sub>PrO</sub> | Beta-sitosterol 3CL<sub>PrO</sub> | Heperetin 3CL<sub>PrO</sub> | Xanthoangelol<sub>E</sub> 3CL<sub>PrO</sub> | Luteolin 3CL<sub>PrO</sub> | Calceolarioside B 3CL<sub>PrO</sub> | Isoquercetin 3CL<sub>PrO</sub> | Sennoside 3CL<sub>PrO</sub> | Sennoside RdRp | Sennoside Spike-ACE2 |
|-------------------|----------------------------|---------------------------------|-----------------------------|---------------------------------|----------------|-----------------|----------------|--------------------|-----------------|---------------------|
| MM/GBSA           |                            |                                 |                             |                                 |                 |                 |                 |                    |                  |
| VDWAALS           | -52.8713                   | -172.9954                       | -163.6940                   | -170.2654                       | -62.0288       | -45.7566        | -38.7973        | -23.4553           | -47.3276        | -34.9620            |
| EEL               | 67.9698                    | -604.9742                       | -672.0357                   | -610.7079                       | -8.5579        | 44.2002         | 123.7085         | -15.2853           | -133.0586       | -34.9601            |
| EGB               | -61.5635                   | 673.5643                        | 720.7120                    | 671.3829                        | 25.4674        | -29.4643        | -100.7974        | 31.6589            | 147.1077        | 67.0213             |
| ESURF             | -6.3440                    | -22.6008                        | -21.9985                    | -22.0860                        | -7.9486        | -5.2809         | -4.7543          | -2.8773            | -7.6417         | -4.9811             |
| DELTA G<sub>gas</sub> | 15.0985                   | -737.5308                       | -791.6253                   | -738.7731                       | -70.5687       | 84.9112         | -38.7405         | -180.3862          | -69.9221        |                     |
| DELTA G<sub>solv</sub> | -67.9075                   | 650.9634                        | 698.7134                    | 649.2969                        | 17.5187        | -34.7452        | -105.5516        | 28.7816            | 139.4660        | 62.0402             |
| DELTA TOTAL        | -52.8900                   | -86.5674                        | -92.9119                    | -89.4762                        | -53.0680       | -36.3016        | -20.6405         | -9.9590            | -40.9203        | -7.8819             |

| MM/PBSA           |                            |                                 |                             |                                 |                 |                 |                 |                    |                  |
| VDWAALS           | -52.8713                   | -172.9954                       | -163.6940                   | -170.2654                       | -62.0288       | -45.7566        | -38.7973        | -23.4553           | -47.3276        | -34.9620            |
| EEL               | 67.9698                    | -604.9742                       | -672.0357                   | -610.7079                       | -8.5579        | 44.2002         | 123.7085         | -15.2853           | -133.0586       | -34.9601            |
| EGB               | -61.5635                   | 673.5643                        | 720.7120                    | 671.3829                        | 25.4674        | -29.4643        | -100.7974        | 31.6589            | 147.1077        | 67.0213             |
| ENPOLAR           | -34.9171                   | -124.0661                       | -116.7880                   | -119.7822                       | -41.3287       | -26.2835        | -24.6040         | -15.9147           | -36.8856        | -25.2096            |
| EDISPER           | 60.2918                    | 243.8727                        | 223.9269                    | 236.2362                        | 74.5756        | 50.7137         | 46.2899          | 33.8181            | 72.2494         | 55.3440             |
| DELTA G<sub>gas</sub> | 15.0985                   | -737.5308                       | -791.6253                   | -738.7731                       | -70.5687       | 84.9112         | -38.7405         | -180.3862          | -69.9221        |                     |
| DELTA G<sub>solv</sub> | -24.6669                   | 715.2173                        | 764.7971                    | 703.3800                        | 72.2978        | 63.8767         | 47.3485          | 194.5854           | 93.5553         |                     |
| DELTA TOTAL        | -9.5684                    | -22.3135                        | -26.8282                    | -35.1931                        | 1.7110         | 0.4745          | 21.0345          | 8.6080             | 14.1991         | 23.6332             |

[Table 3](https://doi.org/10.1371/journal.pone.0268454.t003)
exhibited impressive values ranging from -86.56 to -92.91 kcal/mol. The highest number of binding interactions resulted from the van der Waals interactions with values -163.69 to -172.99 kcal/mol between dimer and the selected ligands. However, the MMGBSA value of vizimpro, a control FDA-approved drug for SARS-CoV-2 exhibited a value of -52.80 kcal/mol. Moreover, the energetics of xanthoangelol_E, beta-sitosterol, and hesperetin as a result of MMPBSA calculations mentioned in Table 3 exhibited values ranging from -22.31 to -26.82 that were striking as compared to the control drug, vizimpro that was -9.56 kcal/mol.

Whereas, energetics of other three compounds namely; luteolin-7-O-glucopyranoside and calceolarioside B, and isoquercetin exhibited MMGBSA calculations that lied between -20.64 to -53.06i kcal/mol. The major contributions came as a result of van der Waals interactions with values ranging from -38.79 to -62.02 kcal/mol. Moreover, total binding energy values from MMPBSA calculations exhibited values ranging from 0.4745 to 21.0345 kcal/mol with mostly contributions from the van der Waals interactions that lied between -45.75 to -62.02 kcal/mol. Furthermore, free energy calculations of all three complexes with sennosides lied from 8.60 to 23.63 kcal/mol, which were comparatively weak as compared to active phytochemicals and the control drug, vizimpro.

**Axial frequency distribution**

AFD was carried out on those complexes that exhibited conformational changes/movements in ligand-receptor complex to attain stability during MD simulations. The findings were consistent with MD simulations analysis that exhibited change in orientation of hesperetin while forcing itself to move deeper into the binding cavity while making interactions between His164@NE2 and the ligand atoms O6. Hesperetin displayed higher density distribution with His143 at the beginning of the simulation, which was later shifted to His41 of the second chain covering more surface area but decreased density distribution as exhibited in Fig 10.

![AFD plots](https://doi.org/10.1371/journal.pone.0268454.g010)
Similarly, xanthoangelol_E and vizimpro exhibited weak hydrogen bonding with His residues in the first 10 ns however it displayed higher density distribution later while retaining stable interactions with the same residue. Both the ligands displayed movement around the active site as seen in Fig 10 and exhibited stronger interactions at the end of simulations.

Moreover, luteolin-7-O-glucopyranoside and calceolarioside_B also exhibited hydrogen bonding between two His residues (His41@O of Chain A and His143@HE2 of chain B) and ligand atoms H35 and O13 in the first 10 ns. Fig 11 exhibits instabilities in density distribution between calceolarioside_B atoms and His residues however the fluctuations in distances are representative of ligand movement between the two chains. Whereas, lutelolin exhibited strong hydrogen bonding with maximum density distribution together with decrease in distance between His143 and the ligand atoms till the end of MD simulations (200 ns), presenting luteolin as more stable than calceolarioside_B. The results from AFD highlight the significance of His residues present in both the chains of 3CL\textsuperscript{pro} that participated in maintaining the stability of all the complexes under study.

**Pharmacokinetic profiling analysis**

**ADMET analysis.** The ADMET analysis exhibited good absorption values of xanthoangelol_E and hesperetin indicating ability of both the compounds to enter blood circulation as compared to beta-sitosterol, and Senna compounds including sennoside A and sennoside B as displayed in Table 4. Notably, only hesperetin presented less blood-brain barrier (BBB)
penetration ability to penetrate CNS as compared to other active phytochemicals that displayed high or very high BBB values. Moreover, hesperetin and beta-sitosterol exhibited good solubility values as compared to xanthoangelol_E, and calceolarioside_B. Furthermore, xanthoangelol_E and beta-sitosterol emerged as non-inhibitors of CYP2D6 exhibiting negative hepatotoxicity and greater than 90% ability to bind to plasma proteins.

Toxicity analysis. The results of TOPKAT are compared with the FDA-approved drugs for the purpose of protocol validation and comparative analysis given in Table 5. The toxicity analysis suggested two active phytochemicals; xanthoangelol_E, and hesperetin as non-carcinogens and non-mutagen as compared to beta-sitosterol and Senna compounds Moreover, the TD50 rat model exhibited values ranging from 148–0.19 mg/Kg body weight as compared to remdesivir that displayed TD50 value 0.96 mg/Kg body weight. Most of the Senna compounds exhibited high TD50 values as compared to hesperetin and beta-sitosterol.

Moreover, the active phytochemicals exhibited rat MTD values ranging from 2.62–0.05 g/Kg body weight while beta-sitosterol displayed lowest MTD values 0.03 g/Kg body weight. Comparatively, FDA-approved drugs including XL-888, vilazadone, and remdesivir presented MTD values of 0.24, 0.93 and 0.09-g/Kg body weights, respectively. Furthermore, the oral LD50 and rat chronic LOAEL values of active phytochemicals stayed within the range of 11.27–0.62 g/Kg body weight and 0.29–0.001 g/Kg body weight, respectively. However, the

Table 4. ADMET properties of chemical compounds present in Senna in comparison with the active phytochemicals and FDA-approved drugs.

| Name               | Absorption level | BBB level | Solubility Level | CYP2D6 | Hepatotoxicity | PPB  |
|--------------------|------------------|-----------|------------------|--------|----------------|------|
| Cynaroside         | 3                | 4         | 3                | FALSE  | TRUE           | FALSE|
| Gallic acid        | 0                | 3         | 4                | FALSE  | TRUE           | FALSE|
| Benzoic acid       | 0                | 3         | 4                | FALSE  | TRUE           | FALSE|
| Kaempferol         | 0                | 3         | 3                | FALSE  | TRUE           | FALSE|
| Isoharmetin        | 0                | 4         | 3                | FALSE  | TRUE           | FALSE|
| Psoralen           | 0                | 2         | 3                | FALSE  | TRUE           | FALSE|
| Syringic acid      | 0                | 3         | 4                | FALSE  | TRUE           | TRUE |
| Vanillic acid      | 0                | 3         | 4                | FALSE  | TRUE           | FALSE|
| Sennoside A        | 3                | 4         | 2                | FALSE  | TRUE           | FALSE|
| Sennoside B        | 3                | 4         | 3                | FALSE  | TRUE           | FALSE|
| Xanthoangelol_E    | 0                | 4         | 2                | FALSE  | FALSE          | TRUE |
| Beta-sisterol      | 3                | 4         | 3                | FALSE  | FALSE          | TRUE |
| Hesperetin         | 0                | 3         | 3                | TRUE   | TRUE           | FALSE|
| Calceolarioside B  | 3                | 4         | 1                | FALSE  | FALSE          | FALSE|
| Isoquercetin       | 3                | 4         | 3                | FALSE  | FALSE          | FALSE|
| Luteolin           | 0                | 4         | 3                | TRUE   | TRUE           | FALSE|
| Vilazadone         | 1                | 4         | 2                | FALSE  | TRUE           | TRUE |
| Lapatinib          | 2                | 4         | 3                | FALSE  | TRUE           | TRUE |
| XL-888             | 1                | 4         | 3                | FALSE  | TRUE           | TRUE |
| Hydroxychloroquine | 0                | 1         | 3                | TRUE   | TRUE           | FALSE|
| Remdesivir         | 3                | 4         | 2                | FALSE  | FALSE          | FALSE|

*Absorption level: (0, good; 1, moderate; 2, poor; 3, very poor)

*BBB level; (0, very high; 1, = high; 2, medium; 3, low; 4, very low)

*Solubility level (0, extremely low; 1, very low; 2, low; 3, good; 4, optimal)

*CYP2D6 prediction: (cutoff score 0.161)

*Hepatotoxicity prediction: (cutoff score -4.154)

*Plasma protein binding (PPB) value: (cutoff score -2.209 presenting >90% binding ability of compounds to the plasma protein.

https://doi.org/10.1371/journal.pone.0268454.1004
LOAEL of beta-sitosterol was lower than other active phytochemicals. Notably, *Senna* compounds came out as ocular irritants but predicted the values of skin irritancy as non-moderate. The statistical data of TOPKAT analysis is exhibited in Table 5.

**Network pharmacological analysis**

482 Covid19 drug target genes were predicted along with 8 xanthoangelol_E drug target genes, 44 target genes for beta-sitosterol, 88 for hesperetin, 24 for calcceolarioside-B, 100 for luteolin, and only 2 for sennosides. Complete details of drug target genes corresponding to phytochemicals are listed in the S4 Table with Uniprot IDs, common names, and target class. Moreover, to generate a network of common interactions between target genes of Covid19 and phytochemicals, only those drug targets were selected that were common between both the groups as presented in Fig 12. Active phytochemicals that were most actively involved in interactions were beta-sitosterol, hesperetin, and luteolin. However, the sennosides failed to exhibit any interactions with Covid19 drug target genes.

The Network pharmacological analysis also highlighted the significance of proposed compounds by identifying common drug targets with Covid19 (presented in Fig 12). The phytochemicals hesperetin, luteolin, and xanthoangelol_E exhibited the maximum number of interactions and identified AKT1, PTGS1, TNF, and DPP4 as the most affected drug targets.

---

**Table 5. Toxicity properties of chemical compounds present in *Senna* in comparison with the active phytochemicals and FDA-approved drugs calculated with TOPKAT.**

| Name                | FDA Rodent Carcinogenicity | \(^a\)Carcinogenic potency TD50 Rat | \(^b\)MTD Oral RD50 Rat | \(^c\)LD50 Oral Rat | \(^d\)MTD Oral Chronic LOAEL | Ames prediction | Skin irritancy | Ocular irritancy |
|---------------------|---------------------------|-------------------------------------|-------------------------|-------------------|----------------------------|----------------|---------------|-----------------|
| Cynaroside          | Non-Carcinogen            | 12.65                               | 1.23                    | 1.35              | 0.03                       | Non-Mutagen     | None          | Moderate        |
| Gallic acid         | Carcinogen                | 101.13                              | 1.85                    | 1.29              | 0.29                       | Non-Mutagen     | None          | Moderate        |
| Benzoic acid        | Single-Carcinogen         | 148.56                              | 1.15                    | 1.60              | 0.28                       | Non-Mutagen     | None          | Moderate        |
| Isorhamnetin        | Non-Carcinogen            | 11.72                               | 0.69                    | 1.20              | 0.11                       | Mutagen         | None          | Mild            |
| Kaempferol          | Non-Carcinogen            | 54.54                               | 1.03                    | 0.95              | 0.14                       | Mutagen         | None          | Moderate        |
| Psoralen            | Multi-Carcinogen          | 16.52                               | 0.05                    | 0.27              | 0.01                       | Non-Mutagen     | Mild          | Mild            |
| Syringic acid       | Non-Carcinogen            | 47.00                               | 0.40                    | 1.84              | 0.16                       | Non-Mutagen     | None          | Moderate        |
| Vanillic acid       | Non-Carcinogen            | 77.02                               | 0.38                    | 2.38              | 0.19                       | Non-Mutagen     | None          | Moderate        |
| Sennoside A         | Non-Carcinogen            | 0.37                                | 1.99                    | 11.27             | 0.08                       | Non-Mutagen     | None          | Mild            |
| Sennoside B         | Non-Carcinogen            | 0.37                                | 1.99                    | 11.27             | 0.08                       | Non-Mutagen     | None          | Mild            |
| Xanthoangelol_E     | Non-Carcinogen            | 131.03                              | 0.46                    | 3.70              | 0.10                       | Non-Mutagen     | Mild          | Mild            |
| Beta-sisterol       | Single-Carcinogen         | 0.71                                | 0.03                    | 1.57              | 0.001                      | Non-Mutagen     | Moderate      | None            |
| Hesperetin          | Non-Carcinogen            | 8.66                                | 0.45                    | 0.925             | 0.07                       | Non-Mutagen     | None          | Mild            |
| Calceolarioside B   | Non-Carcinogen            | 2.17                                | 2.62                    | 5.56              | 0.05                       | Non-Mutagen     | Mild          | Mild            |
| Isoquercetin        | Non-Carcinogen            | 4.54                                | 1.75                    | 0.84              | 0.07                       | Non-Mutagen     | None          | Moderate        |
| Luteolin            | Non-Carcinogen            | 140.46                              | 0.83                    | 0.77              | 0.11                       | Non-Mutagen     | None          | Mild            |
| Vilazadone          | Non-Carcinogen            | 0.93                                | 0.13                    | 1.17              | 0.02                       | Non-Mutagen     | None          | Moderate        |
| Lapatinib           | Non-Carcinogen            | 9.62                                | 0.15                    | 2.22              | 0.01                       | Non-Mutagen     | None          | Mild            |
| XL-888              | Non-Carcinogen            | 0.24                                | 0.08                    | 0.74              | 0.02                       | Non-Mutagen     | None          | Moderate        |
| Hydroxycchloroquine | Non-Carcinogen            | 1.30                                | 0.357                   | 0.20              | 0.03                       | Mutagen         | None          | Severe          |
| Remdesivir          | Non-Carcinogen            | 0.96                                | 0.09                    | 0.27              | 0.001                      | Non-Mutagen     | Mild          | None            |

\(^a\)Tumorigenic dose rate 50 TD50 in unit mg/kg body weight

\(^b\)Maximum tolerated dose MTD in unit g/kg body weight

\(^c\)Median lethal dose LD50 in unit g/kg body weight

\(^d\)Lowest observed adverse effect level LOAEL in unit g/kg body weight.

https://doi.org/10.1371/journal.pone.0268454.t005
While the spread of SARS-CoV-2 is inevitable despite the availability of different vaccines [54], it is imperative to explore every possible treatment to curb this viral disease. Based on viral studies conducted in clinical trials by the U.S. Food and Drug Administration, 2020, the use of combination therapy has been highly recommended such as lopinavir, ritonavir in combination with chloroquine, hydroxychloroquine, and interferon-alpha since they have exhibited potential in the treatment of SARS-CoV-2 infection [55, 56]. Similarly, the combination therapy with natural products has delivered promising results while targeting the specific stages of viral life cycle critical for its survival [57, 58]. It is therefore indispensable to expand the treatment options and include medicinal plants in our research.

In the current study, we derived two pharmacophore models 1) a 3D-QSAR pharmacophore model focused on active phytochemicals that have exhibited biological activity (IC$_{50}$) against 3CL$_{pro}$ with less or no toxicity, and 2) a common feature pharmacophore model derived from _Senna_ compounds due to its popularity in India, Pakistan, China, Thailand, Singapore, South East Asia, and inhabitants of these regions residing in the United States, U.K, and Europe as Covid19 treatment. The ligand-based pharmacophore models were validated with FDA compounds in clinical trials for inhibition of main proteases released by the NCATS...
3D-QSAR pharmacophore model identified HBA, HYD, and RA as common features from the training set of active phytochemicals and validated with a test set. Whereas, a common feature pharmacophore model lacked a significant attribute of hydrophobic groups in its framework that is essential for the bioactivity of 3CL\textsuperscript{pro} [47, 48]. Moreover, the 3D-QSAR pharmacophore also mapped to the FDA-approved drugs vilazodone and lapatinib from the test set that are currently in clinical trials for SARS-CoV-2. Vilazodone is a novel anti-depressant and its use in combination with ritonavir and lopinavir that works by affecting the CYS3A4 is reported to inhibit 3CL\textsuperscript{pro} with IC\textsubscript{50} values below 15 \(\mu\text{M} [59–61]\). Whereas; lapatinib suppressed the SARS-CoV-2 cytopathic effect and cleaved clustering of N protein in MRC5 (human pulmonary fibroblast cell line), thus exhibiting the potential to block 3CL\textsuperscript{pro} [62]. The above results validate the ability of 3D-QSAR pharmacophore to predict the activity of test ligands as active and inactive. Thus, a 3D-QSAR pharmacophore model comprising all the fundamental features for 3CL\textsuperscript{pro} activity proved to be superior to the common feature pharmacophore.

Furthermore, the MD simulations and binding free energy analysis conducted on screened compounds using 3D-QSAR pharmacophore identified xanthoangelol\textsubscript{E}, hesperetin and beta-sitosterol as promising inhibitors of 3CL\textsuperscript{pro} exhibiting binding energy values of -35.1 kcal/mol, -26.9 kcal/mol, and -22.3 kcal/mol respectively. Beta-sitosterol displayed hydrophobic interactions with both the chains of a dimer throughout 200 ns probably because of the hydrophobic constituents in its chemical structures. It is noteworthy that xanthoangelol\textsubscript{E} and hesperetin displayed higher binding energies than beta-sitosterol even though they stayed intact with only one chain of the dimer. The findings of MD simulations revealed the significance of hydrophobic interactions in keeping the ligands intact with a dimer while it has been previously established both computationally and experimentally that only one chain of dimer 3CL\textsuperscript{pro} is active at a time [30]. In agreement with the simulations studies, experimental analysis conducted by Cheng-Wen Lin et al., 2005 [39] on the inhibitory activity of main proteases also revealed xanthoangelol\textsubscript{E} as the most active compound against 3CL\textsuperscript{pro} and PL\textsuperscript{pro} with IC\textsubscript{50} values (11.4 ± 1.4 \(\mu\text{M}\) and (1.2 ± 0.4 \(\mu\text{M}\) respectively [38]. In another study by Park et al. 2016, hesperetin and beta-sitosterol were reported to be capable of inhibiting main protease dose-dependently in both the cell-free and cell-based assays with the IC\textsubscript{50} value of 8.3\(\mu\text{M}\) and 115 \(\mu\text{M}\), respectively [39]. Keeping in view the scope of this study and capability of these compounds in experimental assays to inhibit both the 3CL\textsuperscript{pro} and PL\textsuperscript{pro}, we also subjected PL\textsuperscript{pro} to molecular docking followed by 50 ns MD simulations on top complexes (S5 and S6 Tables), which can be used as a lead to design more specific dual inhibitors in future (S8 Fig). The structural insights of these compounds might offer clues for development of anti-SARS-CoV-2 drugs and could be used in combination as alternate medicine to prevent Covid19 infection.

In comparison, the secondary metabolites like sennosides A, B, C, and D present in higher percentage in \textit{Senna} [12] exhibited instability and weak binding affinity during computational analysis against 3CL\textsuperscript{pro}. Furthermore, to explore the possibility of binding of \textit{Senna} compounds with other Covid19 target proteins, we expanded the prospect of our research. The findings suggested that \textit{Senna} compounds failed to act as a candidate of high ligand affinity capable of disrupting contact between the spike protein RBD and ACE2 receptor. Moreover, these sennoside ligands completely left binding sites of all other targets namely helicase nsp13, spike-ACE2, and 3CL\textsuperscript{pro} except RdRp nsp12 exhibited in Fig 9, which also resulted in displacement of sennoside with weak binding energy (14.199 kcal/mol). The ADMET and TOPKAT protocols have also marked few \textit{Senna} compounds as carcinogens and mutagens after undergoing rat carcinogenicity, TD50, LD50, and LOAEL tests. In conclusion, these findings discredit the use of \textit{Senna} tea as whole with all its chemical constituents in Covid19 treatment, which can rather be harmful in the absence of insufficient clinical data.
However, as an outcome of this work, it is suggested as a matter of general global dissemination that *Senna* tea has nothing to do with the killing of the SARS-CoV-2. This unintentionally held us responsible for deaths of geriatric patients particularly, via diuresis/dehydration/kidney failure through overconsumption of *Senna* tea. Negation of false claim through scientific research is necessary not only to reduce overall burden but at the same time uncertified facts when disseminated through the electronic and print media, is and can remain a curse under the situation of deadly pandemic [https://twitter.com/i/status/1262403722006724608](https://twitter.com/i/status/1262403722006724608). Statements without proper workout from renowned personalities are cherry on top that may have disastrous impact to an already poverty and/or illiteracy hit regions of the world, which is avoidable [63]. While our analysis has a limitation of providing a predictive viewpoint of *Senna* compounds in the absence of experimental data on this plant, further clinical analysis should be considered and implemented in the future. Our study hints and thus recommends that the use of media to propagate any unscientific thought or actions without scientific cura-
cation and clarification must be discouraged worldwide. This also urges the need for a scientific body from the WHO platform to control the propagation of scientific information in a manner to prevent a wider community worldwide from spreading unchecked information under the
disguise of scientific nomenclature.

**Supporting information**

S1 Table. Small molecule medicinal inhibitors of 3CL\textsuperscript{pro} with reported activity (IC\textsubscript{50} values) against SARS-CoV-2 selected as training set for 3D-QSAR pharmacophore modeling. (DOCX)

S2 Table. Chemical compounds of *Senna alexandrina* of *Cassia senna* and *Tinnevelly senna* of *Cassia angustifolia* used for common feature pharmacophore modeling and molecular docking. (DOCX)

S3 Table. Statistical variations of common feature pharmacophore models. (DOCX)

S4 Table. Complete details of drug target genes corresponding to proposed phytochemicals used in network pharmacological analysis. (DOCX)

S5 Table. GOLD docking scores of proposed medicinal compounds with additional phytochemicals docked in the active cavity of 3CL\textsuperscript{pro}. (DOCX)

S6 Table. GOLD docking scores of proposed medicinal compounds with additional phytochemicals docked in the active cavity of PL\textsuperscript{pro}. (DOCX)

S1 Fig. a) 3D-QSAR pharmacophore exhibits four common features consisting of 1 hydrogen bond acceptor (HBA), 2 hydrophobic (HYD), and 1 ring aromatic (RA) b) 3D-QSAR pharmacophore model with distance between chemical features. c) The most active medicinal compound; xanthoangelol\textsubscript{E} from the training set mapped with the highest FitValue of 4.36 d) The top compound, vilazodone mapped against 3D-QSAR pharmacophore with the highest FitValue of 3.56 from the test set. e) The second top compound lapitinib with a FitValue of 3.54 mapped against 3D-QSAR pharmacophore from the test set. (TIIF)
S2 Fig. a) Common feature pharmacophore results of Senna compounds exhibit four common features consisting of 3 hydrogen bond acceptors (HBA) and 1 ring aromatic (RA) features b) Common feature pharmacophore model with distance between chemical features. c) Isoquercetin mapped the common feature pharmacophore with highest FitValue of 0.99 from the training set. d) Compound with lowest FitValue.

S3 Fig. Preferred binding mode of active phytochemicals in the binding site of 3CL\textsuperscript{pro} depicting two-dimensional (2D) docked complex with a) Xanthoangelol\textsubscript{E} having an IC\textsubscript{50} value 11.4 ±1.4 μM b) Hesperetin having an IC\textsubscript{50} value 8.3 μM c) Beta-sitosterol with an IC\textsubscript{50} value 1210 μM.

S4 Fig. Preferred binding mode of active phytochemicals in the binding site of 3CL\textsuperscript{pro} depicting two-dimensional (2D) docked complex with a) Luteolin-7-O-glucopyranoside b) Calceolarioside\textsubscript{B} c) Isoquercetin.

S5 Fig. Insights into the MD simulations of vizimpro, hesperetin, beta-sitosterol, and xanthoangelol\textsubscript{E} for the time period of 200 ns each complex. a) RMSD in complex with 3CL\textsuperscript{pro} b) Radius of gyration c) RMSF of 3CL\textsuperscript{pro} residues d) Beta-factor.

S6 Fig. Insights into the MD simulations of vizimpro, luteolin, calceolarioside\textsubscript{B}, and isoquercetin for the time period of 200 ns each complex a) RMSD in complex with 3CL\textsuperscript{pro} b) Radius of gyration c) RMSF d) Beta-factor.

S7 Fig. RMSD graphs of extended MD simulations of compounds that exhibited instability till 200 ns. a) 100 ns of extended MD simulations of xanthoangelol\textsubscript{E} b) 200 ns of extended MD simulations of calceolarioside\textsubscript{B} c) 100 ns of extended MD simulations of isoquercetin.

S8 Fig. RMSD of 50 ns MD simulations of corylifol\textsubscript{A} and papyriflavonol\textsubscript{A} docked at PL\textsuperscript{pro} active site.

Acknowledgments

We are generally thankful to Pakistan-United States Science and Technology Cooperation Program and Higher Education Commission (HEC), Pakistan for financial assistance of Computational Biology Lab.

Author Contributions

Conceptualization: Naila Zaman, Syed Sikander Azam.
Data curation: Ghulam Abbas.
Formal analysis: Naila Zaman.
Methodology: Naila Zaman, Nousheen Parvaiz, Rabia Farid, Afifa Navid, Syed Sikander Azam.
Project administration: Syed Sikander Azam.
**Supervision:** Syed Sikander Azam.

**Validation:** Naila Zaman.

**Writing – original draft:** Naila Zaman, Nousheen Parvaiz, Rabia Farid, Afifa Navid.

**Writing – review & editing:** Naila Zaman, Syed Sikander Azam.

**References**

1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [cited 15 Jun 2021]. Available: https://covid19.who.int/

2. Different COVID-19 Vaccines | CDC [Internet]. [cited 15 Jun 2021]. Available: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html

3. The coronavirus pandemic is far from over | Science in-depth reporting on science and technology | DW | 11.06.2021 [Internet]. [cited 15 Jun 2021]. Available: https://www.dw.com/en/coronavirus-global-pandemic-trend/a-53954594

4. Viana J, van Dorp CH, Nunes A, Gomes MC, van Boven M, Kretzschmar ME, et al. Controlling the pandemic during the SARS-CoV-2 vaccination rollout. Nat Commun. 2021; 12: 3674. https://doi.org/10.1038/s41467-021-23938-8 PMID: 34135335

5. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021; 397: 1023–1034. https://doi.org/10.1016/S0140-6736(21)00306-8 PMID: 33587887

6. Vandebroek I, Pieroni A, Stepp JR, Hanazaki N, Ladio A, Alves RRN, et al. Reshaping the future of ethnobiology research after the COVID-19 pandemic. Nat Plants. 2020; 6: 723–730. https://doi.org/10.1038/s41477-020-0691-6 PMID: 32572213

7. Mohammad S, Jafari B, Asgharian P, Martorell M, Sharifi-Rad J. Medicinal plants used in the treatment of Malaria: A key emphasis to Artemisia, Cinchona, Cryptolepis, and Tabebuia genera. Phytother Res. 2020; 34: 1556–1569. https://doi.org/10.1002/ptr.6628 PMID: 32022345

8. Gao D, Niu M, Wei S-Z, Zhang C-E, Zhou Y-F, Yang Z-W, et al. Identification of a Pharmacological Biomarker for the Bioassay-Based Quality Control of a Thirteen-Component TCM Formula (Lianhua Qingwen) Used in Treating Influenza A Virus (H1N1) Infection. Front Pharmacol. 2020; 11: 746. https://doi.org/10.3389/fphar.2020.00746 PMID: 32523531

9. Growing demand drives herb prices up [Internet]. [cited 20 Jun 2021]. Available: https://www.thenews.com.pk/print/669097-growing-demand-drives-herb-prices-up

10. Kumar S, Naem R, Radhawi AST, Mahmood SU, Batool Z, Naqi SRA. Senna Makki and the COVID-19 pandemic: a reflection from Pakistan. Int J Community Med Public Health. 2020; 7: 723–730. https://doi.org/10.18203/2394-6040.ijcmphp20205205

11. Zhao Y, Zhao K, Jiang K, Tao S, Li Y, Chen W, et al. A Review of Flavonoids from Cassia Species and their Biological Activity. Curr Pharm Biotechnol. 2016; 17: 1134–1146. https://doi.org/10.2174/1389201017666160819151153 PMID: 27538998

12. Elansary HO, Szopa A, Kubica P, Eikiert H, Ali HM, Elshikh MS, et al. Bioactivities of traditional medicinal plants in alexandria. Evid Based Complement Alternat Med. 2018; 2018: 1463579. https://doi.org/10.1155/2018/1463579 PMID: 29636772

13. Beuers U, Spengler U, Pape GR. Hepatitissy after chronic abuse of senna. Lancet. 1991; 337: 372–373. https://doi.org/10.1016/0140-6736(91)91012-j PMID: 1671276

14. Sindh governor claims herbs helped him recover from coronavirus—Pakistan—DAWN.COM [Internet]. [cited 25 Feb 2022]. Available: https://www.dawn.com/news/1557883

15. Bashir A, Sizar O. Laxatives. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. https://doi.org/10.1016/B978-0-444-53717-1.00960-4

16. Senna: Health Benefits, Side Effects, Uses, Dose & Precautions [Internet]. [cited 20 Jun 2021]. Available: https://www.rxlist.com/senna/supplements.htm

17. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guideline Panel: Chair:; Panel members, EASL Governing Board representative: EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019; 70: 1222–1261. https://doi.org/10.1016/j.jhep.2019.02.014

18. Kim Y, Lovell S, Tiew K-C, Mandadapu SR, Alliston KR, Batalla KE, et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol. 2012; 86: 11754–11762. https://doi.org/10.1128/JVI.01348-12 PMID: 22915796
19. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270–273. https://doi.org/10.1038/s41586-020-2012-7 PMID: 32015507

20. Ahmad S, Navid A, Farid R, Abbas G, Ahmad F, Zaman N, et al. Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics. Eur J Pharm Sci. 2020; 151: 105387. https://doi.org/10.1016/j.ejps.2020.105387 PMID: 32454128

21. Ryu YB, Jeong HJ, Kim JH, Kim YM, Park J-Y, Kim D, et al. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition. Bioorg Med Chem. 2010; 18: 7940–7947. https://doi.org/10.1016/j.bmc.2010.09.035 PMID: 20934345

22. Park J-Y, Kim JH, Kwon JM, Kwon H-J, Jeong HJ, Kim YM, et al. Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava. Bioorg Med Chem. 2013; 21: 3730–3737. https://doi.org/10.1016/j.bmc.2013.04.026 PMID: 23647823

23. Jo S, Kim S, Shin DH, Kim M-S. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem. 2020; 35: 145–151. https://doi.org/10.1080/14756366.2019.1690480 PMID: 31724441

24. Kc GB, Bocci G, Verma S, Hassan MM, Holmes J, Yang JJ, et al. A machine learning platform to estimate anti-SARS-CoV-2 activities. Nat Mach Intell. 2021; https://doi.org/10.1038/s42256-021-00335-w

25. Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, et al. ChEMBL web services: streamlining access to drug discovery data and utilities. Nucleic Acids Res. 2015; 43: W612–20. https://doi.org/10.1093/nar/gkv352 PMID: 25883136

26. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Machine learning to estimate anti-SARS-CoV-2 activities. Nat Mach Intell. 2021; https://doi.org/10.1038/s42256-021-00335-w

27. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25: 1605–1612. https://doi.org/10.1002/jcc.20084 PMID: 15264254

28. Rahman MM, Hossain HA, Islam S, Khan MM, Khan IM, et al. Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations. Int J Mol Sci. 2020; 21: 1189. https://doi.org/10.3390/ijms21151189 PMID: 32731361

29. Pfizer’s Vizimpro is among 3 FDA-approved drugs that combat COVID-19 in lung cells: report | Fierce-Biotech [Internet]. [cited 17 Jun 2021]. Available: https://www.fiercebiotech.com/research/pfizer-s-vizimpro-among-three-fda-approved-drugs-combat-covid-lung-cells-report

30. The Amber Molecular Dynamics Package [Internet]. [cited 16 Jun 2021]. Available: https://ambermd.org/

31. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996; 14: 33–8, 27. https://doi.org/10.1016/0263-7855(96)00018-5 PMID: 8744570

32. Pinar A, Ceylan H, Tekin I, Bülent D. Amino acid substitutions in the S protein of SARS-CoV-2. J Mol Model. 2021; 27: 200. https://doi.org/10.1007/s00894-021-04426-3 PMID: 34083577

33. Raza S, Azam SS. AFD: an application for bi-molecular interaction using axial frequency distribution. J Mol Model. 2018; 24: 84. https://doi.org/10.1007/s00894-018-3601-3 PMID: 29511825

34. Park J-Y, Ko J-A, Kim DW, Kim YM, Kwon H-J, Jeong HJ, et al. Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV. J Enzyme Inhib Med Chem. 2016; 31: 23–30. https://doi.org/10.1007/s10529-014-9767-5 PMID: 25683083

35. Lin C-W, Tsai F-J, Tsai C-H, Lai C-C, Lai T-Y, et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 2005; 68: 36–42. https://doi.org/10.1016/j.antiviral.2005.07.002 PMID: 16115693
40. Parks JM, Smith JC. How to discover antiviral drugs quickly. N Engl J Med. 2020; 382: 2261–2264. https://doi.org/10.1056/NEJMcbr2007042 PMID: 32433861

41. Aziz N, Kim M-Y, Cho JY. Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. J Ethnopharmacol. 2018; 225: 342–358. https://doi.org/10.1016/j.jep.2018.05.019 PMID: 29801717

42. Douangamath A, Fearon D, Gehrz T, Lukacik P, Owen CD, et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun. 2020; 11: 5047. https://doi.org/10.1038/s41467-020-18709-w PMID: 33028810

43. Mody V, Ho J, Willis S, Mawri A, Lawson L, Ebert M, et al. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun Biol. 2021; 4: 93. https://doi.org/10.1038/s42003-020-01577-x PMID: 33473151

44. Ribas J, Cubero E, Luque FJ, Orozco M. Theoretical study of alkyl-pi and aryl-pi interactions. Reconciling theory and experiment. J Org Chem. 2002; 67: 7057–7065. https://doi.org/10.1021/jo0201225 PMID: 12354000

45. Ramos-Guzmán CA, Ruiz-Pernía JJ, Tuñón I. Unraveling the SARS-CoV-2 Main Protease Mechanism Using Multiscale Methods. ACS Catal. 2020; 10: 12544–12554. https://doi.org/10.1021/acscatal.0c03420 PMID: 34192089

46. Ferreira JC, Fadl S, Villanueva AJ, Rabeh WM. Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease. Front Chim. 2021; 9: 692168. https://doi.org/10.3389/fchem.2021.692168 PMID: 34249864

47. Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitruc AC, Chen W, et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun. 2020; 11: 4541. https://doi.org/10.1038/s41467-020-18319-6 PMID: 32917884

48. Goc A, Sumera W, Rath M, Niedzwiecki A. Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions. PLoS One. 2021; 16: e0253489. https://doi.org/10.1371/journal.pone.0253489 PMID: 34138966

49. Wang Y, Liu M, Gao J. Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. Proc Natl Acad Sci USA. 2020; 117: 13967–13974. https://doi.org/10.1073/pnas.2008209117 PMID: 32503918

50. Huang Y, Yang C, Xu X-F, XU W, Liu S-W. Structural and functional properties of SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. Acta Pharmacol Sin. 2020; 41: 1141–1149. https://doi.org/10.1038/s41401-020-0485-4 PMID: 32747721

51. Bassendine MF, Bridge SH, McCaughan GW, Gorrell MD. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity? J Diabetes. 2020; 12: 649–658. https://doi.org/10.1111/1753-0407.13052 PMID: 32394639

52. Khezri MR. PI3K/AKT signaling pathway: a possible target for adjuvant therapy in COVID-19. Hum Cell. 2021; 34: 700–701. https://doi.org/10.1007/s13577-021-00484-5 PMID: 33432441

53. Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol. 2020; 57: 779–783. https://doi.org/10.1007/s00592-020-01539-z PMID: 32506195

54. Begum J, Mir NA, Dev K, Buyamayum B, Wani MY, Raza M. Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development. Transbound Emerg Dis. 2021; 68: 1111–1124. https://doi.org/10.1111/tbed.13804 PMID: 32815655

55. Li H, Wang YM, Xu JY, Cao B. [Potential antiviral therapeutics for 2019 Novel Coronavirus]. Zhonghua Jie He Hu Xi Za Zhi. 2020; 43: 170–172. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.004 PMID: 32164080

56. Khan Z, Karatas y, Ceylan AF, Rahman H. COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts. Le Pharmacien Hospitalier et Clinicien. 2020; https://doi.org/10.1016/j.phclin.2020.06.003

57. Su H, Xu Y, Jiang H. Drug discovery and development targeting the life cycle of SARS-CoV-2. Fundamental Research. 2021; 1: 151–165. https://doi.org/10.1016/j.fmre.2021.01.013

58. Du H-Z, Hou X-Y, Miao Y-H, Huang B-S, Liu D-H. Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP). Chin J Nat Med. 2020; 18: 206–210. https://doi.org/10.1016/S1875-5364(20)30022-4 PMID: 32245590

59. Mohebbi N, Talebi A, Moghadamnia M, Nazari Taloki Z, Shakiba A. Drug Interactions of Psychiatric and COVID-19 Medications. Basic Clin Neurosci. 2020; 11: 185–200. https://doi.org/10.32598/bcn.11. covid19.2500.1 PMID: 32855778
60. Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016; 106: 72–86. https://doi.org/10.1016/j.phrs.2016.02.014 PMID: 26896788

61. Ghasemi-yeh P, Mortazavi N, Karimzadeh I, Vazin A, Mahmoudi L, Moghimi-Sarani E, et al. Psychiatric Adverse Drug Reactions and Potential Anti-COVID-19 Drug Interactions with Psychotropic Medications. Iran J Pharm Res. 2021; 20: 66–77. https://doi.org/10.22037/ijpr.2021.114717.15007 PMID: 34903970

62. Raymonda MH, Ciesla JH, Monaghan M, Leach J, Asantewaa G, Smorodintsev-Schiller LA, et al. Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro. BioRxiv. 2020; https://doi.org/10.1101/2020.11.25.398859

63. He’s a Nobel laureate. Critics say he was misleading on Covid—STAT [Internet]. [cited 20 Jun 2021]. Available: https://www.statnews.com/2021/05/24/stanford-professor-and-nobel-laureate-critics-say-he-was-dangerously-misleading-on-covid/